MS Pharma has launched a new biologics manufacturing plant in Saudi Arabia, investing $50 million, according to company sources. The facility is equipped for formulation, fill and finish, and lyophilization, aiming to serve both local and international pharmaceutical markets.
Designed to comply with leading global standards, including those set by the EMA and U.S. FDA, the factory specializes in monoclonal antibodies and complex peptides. Notably, it houses the region’s first in-house bioanalytical testing labs, speeding up the approval process for essential medicines by removing the need for overseas testing.
Ghiath Sukhtian, Chairman of MS Pharma, described the opening as a significant milestone for the company and the region’s biopharmaceutical sector. Kalle Känd, CEO, emphasized that the facility not only boosts production capacity but also supports partnerships, workforce development, and technology transfer, furthering national and regional healthcare objectives.
